Preferred Label : Adult B Acute Lymphoblastic Leukemia;
NCIt synonyms : B Cell Adult Acute Lymphoblastic Leukemia; Adult Precursor B-Lymphoblastic Leukemia; Adult B Cell ALL; Adult B-Cell Acute Lymphoblastic Leukemia; Adult B Cell Acute Lymphoblastic Leukemia; B Cell Adult ALL; B-Cell Adult Acute Lymphoblastic Leukemia; B-Cell Adult ALL; Adult B-Cell ALL; Adult B-Cell Acute Lymphocytic Leukemia; Adult B Cell Acute Lymphocytic Leukemia; Adult Precursor B Lymphoblastic Leukemia; B Cell Adult Acute Lymphocytic Leukemia; B-Cell Adult Acute Lymphocytic Leukemia;
NCIt related terms : B Acute Lymphoblastic Leukemia;
NCIt definition : A B acute lymphoblastic leukemia that occurs during adulthood.;
Neoplastic status : Malignant;
Origin ID : C9143;
UMLS CUI : C0279593;
Automatic exact mappings (from CISMeF team)
DO Cross reference
Disease excludes abnormal cell
Disease excludes normal cell origin
Disease may have findings
Has associated anatomic sites
Semantic type(s)
concept_is_in_subset
disease_excludes_finding
disease_has_abnormal_cell
disease_has_finding
disease_has_molecular_abnormality
disease_has_normal_cell_origin
disease_has_normal_tissue_origin
disease_has_primary_anatomic_site
disease_may_have_associated_disease
disease_may_have_molecular_abnormality
https://www.ema.europa.eu/medicines/human/EPAR/Blincyto
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
infusions, intravenous
blinatumomab
blinatumomab
antineoplastic agents
antineoplastic agents
adult
Adult B Acute Lymphoblastic Leukemia
precursor b-cell lymphoblastic leukemia-lymphoma
Philadelphia chromosome negative
Measurable Residual Disease
neoplasm recurrence, local
orphan drug production
drug approval
europe
pregnancy
breast feeding
drug interactions
drug evaluation
syndication feed
drug evaluation, preclinical
product surveillance, postmarketing
treatment outcome
blinatumomab
antibodies, bispecific
antibodies, bispecific
---
https://ansm.sante.fr/tableau-atu-rtu/blincyto-38-5-microgrammes-poudre-pour-solution-a-diluer-pour-perfusion
2015
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
infusions, intravenous
blinatumomab
blinatumomab
antineoplastic agents
antineoplastic agents
continuity of patient care
pharmacovigilance
adult
Adult B Acute Lymphoblastic Leukemia
precursor b-cell lymphoblastic leukemia-lymphoma
Philadelphia chromosome negative
Measurable Residual Disease
neoplasm recurrence, local
blinatumomab
antibodies, bispecific
antibodies, bispecific
---